Le Lézard
Classified in: Health, Business, Sports and recreation
Subject: LIC

Elyria School District and Mercy Health Partner in Naming Rights Deal


ELYRIA, Ohio, Sept. 10, 2018 /PRNewswire-PRWeb/ -- Elyria City Schools Board of Education tonight approved a long-term partnership with Mercy Health for naming rights to the football field at Ely Stadium. The new name effective today is now called Mercy Health Field at Ely Stadium.

Under the terms of the agreement, the deal is for the next 10 years at the terms of $35,000 per year. It is worth a total of $350,000, to the school district over the life of the agreement .

"This is a great thing from the perspective of athletics and from that of the school community as a whole," said Dr. Thomas Jama, Superintendent of Elyria Schools. "Mercy Health's investment supports the financial aspects of the construction project itself, but it also opens the door for the district and Mercy Health to explore future healthcare opportunities that benefit all students in the Elyria Schools.

"Empowering youth to remain physically and mentally fit is part of our promise and today, this field represents that promise coming to life." Said Edwin Oley, Chief Executive Officer at Mercy Health.

"Mutually beneficial partnerships have an exponential effect in deepening the roots a company has in a community they're serving," said Larry Jaeger, President of Sponsor Burst, a sports marketing company that specializes in naming rights and who helped facilitate the agreement. "Naming rights sponsorships have become an invaluable component of a company's marketing strategy."

 

SOURCE Mercy Health; Elyria School District


These press releases may also interest you

at 16:05
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today...

at 16:05
Biodesix, Inc. , a leading diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the first quarter ended March 31, 2024, and provided a corporate update. "I am very pleased to announce...

at 16:05
Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the first quarter ended March 31, 2024,...

at 16:05
Mind Medicine (MindMed) Inc. , (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the quarter ended March 31, 2024,...

at 16:05
Personalis, Inc. , a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2024 ended March 31, 2024, and provided recent business highlights. Recent Business Highlights The analytical...

at 16:05
Xenon Pharmaceuticals Inc. , a neuroscience-focused biopharmaceutical company, today announced that the company will present at the BofA Securities Health Care Conference 2024 taking place May 14-16, 2024 in Las Vegas, NV. Fireside Chat Presentation...



News published on and distributed by: